摘要
[目的]观察DHA复合物(AT158)的抑癌作用。[方法]以H22肝癌细胞的荷瘤小鼠为体内实验模型做三批,以U251星形胶质瘤细胞、SKOV3卵巢癌细胞为体外培养实验模型,研究了AT158在体内和体外对各种癌细胞的抑制作用。[结果]在体内AT158低中高剂量组对22肝癌细胞抑瘤率分别为37.62%,48.55%,58.63%,在体外对U251星形胶质瘤细胞IC50为0.37μg/ml(0.33～0.41μg/ml)、对SKOV3卵巢癌细胞IC50为0.52μg/ml(0.50～0.52μg/ml)。[结论]AT158是具有抑癌作用,具有很高的开发价值。
[Objective]To inquire into the anti-tumor mechanism of the anticarclnogen AT-158. [Methods]Using mice bearing with HepA22 in vivo and U251 ,SKOV-3 cell lines in vitro,we studied the effect of AT-158 on the different canc- er cells. [Results]AT-158 could inhibit the growth of Hep22 in vivo： the antltumor rate is 37.62% （low dose）, 48.55% （middle dose） and 58.63%（high dose） and also AT-158 can inhibk the growth of U251 ,SKOV-3 in vitro：IC50 to U251 is 0. 37μg/ml（ 0. 33-0. 41μg/ml） and IC50 to SKOV-3 is 0. 52μg/ml（ 0, 50-0, 52μg/ml）. [Conclusion]AT-158 is promised to be a highly effective antl-tumor drug with wide prospect.
出处
《预防医学论坛》
2005年第5期567-569,共3页
Preventive Medicine Tribune
